Beyond Benefits: The Unseen Risks of GLP-1 Receptor Agonists in Recent Trials | ||||
| Zagazig Journal of Pharmaceutical Sciences | ||||
| Volume 33, Issue 2, December 2024, Page 22-24 PDF (242.38 K) | ||||
| Document Type: Review Articles | ||||
| DOI: 10.21608/zjps.2024.340729.1080 | ||||
 View on SCiNiTO | ||||
| Author | ||||
Mahmoud H Elbatreek 
| ||||
| Department of Pharmacology, Faculty of Pharmacy, Zagazig Univerity | ||||
| Abstract | ||||
| Abstract Recent attention has focused on GLP-1 receptor agonists (GLP-1RAs) for their therapeutic potential beyond obesity and diabetes, exploring applications in cardiovascular disorders, neurodegenerative diseases, and more. However, their use is accompanied by notable risks, particularly the loss of lean body mass. Studies indicate that muscle mass loss can constitute 25% to 39% of total weight loss, with variability in clinical findings. This reduction in muscle is linked more to overall weight loss than direct pharmacological effects, raising concerns about sarcopenia, especially in older adults. Additionally, GLP-1RAs may induce a slight increase in heart rate, the long-term implications of which remain unclear, particularly for patients with heart failure. As these medications reshape treatment paradigms, ongoing research is crucial to fully understand their benefits and risks, ensuring safe and effective clinical use. This commentary underscores the need for vigilance regarding the adverse effects of GLP-1RAs as their applications expand. . . | ||||
| Keywords | ||||
| GLP-1RA; lean mass; semaglutide; tirzepatide | ||||
|
Statistics Article View: 160 PDF Download: 111 |
||||
